Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA3 | P07451 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9380420 | 0.86 | PIK3CG (0.56) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL4019751 | 0.82 | MAPT (0.61) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL240344 | 0.82 | RAB9A (0.63) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL18405092 | 0.79 | MAPT (0.53) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL20748550 | 0.79 | MAPT (0.53) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL4025674 | 0.79 | MAPT (0.53) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL17153860 | 0.79 | CA12 (0.45) | MAPTALOX15CA12CA2CA3 | |
| SCHEMBL17221544 | 0.79 | GAA (0.51) | MAPTLMNAMAPK1CA12CA2 | |
| SCHEMBL13765046 | 0.78 | MAPT (0.51) | MAPTALOX15LMNACYP1A2THRB | |
| SCHEMBL30058638 | 0.78 | PSMB8 (0.59) | MAPTALOX15CA12CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | claimed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | claimed |
| EP-2678016-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC | 2015-11-12 | — | — | US | disclosed |
| WO-2014151147-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | ENANTA PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7563877-B2 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | WANG GUOQIANG | 2008-10-23 | — | — | US | disclosed |
| US-7384922-B2 | 6-11 bridged oxime erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | ENANTA PHARMACEUTICALS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041618-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | MAPT 4013/4885ALOX15 609/4885LMNA 4380/4885 |
| US-20070207972-A1 | Processes for the preparation of 0-(2-aminobenzo[d]oxazol-5-yl)methyl hydroxylamine for the synthesis of 6,11-bicyclic erythromycin derivative EDP-182 | DHPS, TET1, TET2 | MAPT 4438/4885ALOX15 2775/4885LMNA 1591/4885 |
| US-20150320727-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | MAPT 2704/4885ALOX15 2381/4885LMNA 2098/4885 |
| US-20080262208-A1 | 6-11 Bridged Oxime Erythromycin Derivatives | CYP2D6, CYP2B6, CYP1B1 | MAPT 4013/4885ALOX15 609/4885LMNA 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.